Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Gritstone bio, Inc. (GRTSQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -1.208x
Based on the latest financial reports, Gritstone bio, Inc. (GRTSQ) has a cash flow conversion efficiency ratio of -1.208x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.81 Million) by net assets ($22.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gritstone bio, Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Gritstone bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Gritstone bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gritstone bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Next.e.GO N.V.
NASDAQ:EGOXF
|
-0.009x |
|
Exobox Tech Corp
PINK:EXBX
|
-0.012x |
|
Neurogenesis Inc
PINK:NEUN
|
N/A |
|
MotorVac Technologies Inc
PINK:MVAC
|
0.050x |
|
Transtech Industries Inc
PINK:TRTI
|
0.016x |
|
LEEP Inc
PINK:LPPI
|
0.366x |
|
Interact-TV Inc
PINK:ITVI
|
0.015x |
|
Vasamed Inc
PINK:VSMD
|
0.103x |
Annual Cash Flow Conversion Efficiency for Gritstone bio, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Gritstone bio, Inc. from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $51.85 Million | $-121.65 Million | -2.346x | -245.57% |
| 2022-12-31 | $170.78 Million | $-115.95 Million | -0.679x | -189.48% |
| 2021-12-31 | $216.09 Million | $-50.68 Million | -0.235x | +56.11% |
| 2020-12-31 | $166.74 Million | $-89.10 Million | -0.534x | -- |